SCHEMBL1047925

SCHEMBL1047925

[CH2]C=Cc1c(OC)cc(OC)cc1OC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 8/20 0.56
CYP1B1 Q16678 8/20 0.56
CYP1A2 P05177 7/20 0.56
ABCG2 Q9UNQ0 1/20 0.51
ERN1 O75460 1/20 0.48
MAOA P21397 2/20 0.45
AURKA O14965 1/20 0.43
LMNA P02545 1/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2C19 P33261 2/20 0.42
ALDH1A1 P00352 2/20 0.42
CYP2E1 P05181 1/20 0.42
CYP2C8 P10632 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2A6 P11509 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP4B1 P13584 1/20 0.42
CYP2B6 P20813 1/20 0.42
CYP3A5 P20815 1/20 0.42
CYP2A7 P20853 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1047924 1.00 CYP1A1 (0.56) CYP1A1CYP1B1CYP1A2ABCG2ERN1
SCHEMBL7868949 0.80 CYP1A1 (0.58) CYP1A1CYP1B1CYP1A2ABCG2ERN1
SCHEMBL3475991 0.80 CYP1A1 (0.58) CYP1A1CYP1B1CYP1A2ABCG2ERN1
SCHEMBL3475990 0.80 CYP1A1 (0.58) CYP1A1CYP1B1CYP1A2ABCG2ERN1
SCHEMBL10603021 0.80 CYP1A1 (0.58) CYP1A1CYP1B1CYP1A2ABCG2ERN1
SCHEMBL18480811 0.78 CYP1A1 (0.56) CYP1A1CYP1B1CYP1A2ABCG2ERN1
SCHEMBL5187642 0.77 ERN1 (0.52) CYP1A1CYP1B1CYP1A2ABCG2ERN1
SCHEMBL2096170 0.77 ERN1 (0.55) CYP1A1CYP1B1CYP1A2ABCG2ERN1
SCHEMBL1045559 0.76 CYP1A1 (0.53) CYP1A1CYP1B1CYP1A2ABCG2ERN1
SCHEMBL1045558 0.76 CYP1A1 (0.53) CYP1A1CYP1B1CYP1A2ABCG2ERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150224099-A1 ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS OTSUKA PHARMA CO LTD (JP) 2015-08-13 US disclosed
US-8987304-B2 Antituberculous composition comprising oxazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2015-03-24 US disclosed
EP-2269694-A2 Antituberculous composition comprising oxazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2011-01-05 EP disclosed
EP-2116527-A1 OXIME COMPOUND, PHOTOSENSITIVE COMPOSITION, COLOR FILTER, METHOD FOR PRODUCTION OF THE COLOR FILTER, AND LIQUID CRYSTAL DISPLAY ELEMENT FUJIFILM Corporation (JP) 2009-11-11 EP disclosed
US-20090275528-A1 ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-11-05 US disclosed
WO-2007043542-A9 ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS OTSUKA PHARMA CO LTD (JP) 2008-05-08 WO disclosed
US-20030129504-A1 Photosensitive resin compositon, transfer material, image forming method, color filter and producing method thereof and photomask and producing method thereof FUJI PHOTO FILM CO., LTD. 2003-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150224099-A1 ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 CYP1A1 276/4885CYP1B1 201/4885CYP1A2 135/4885
US-20090275528-A1 ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 CYP1A1 276/4885CYP1B1 201/4885CYP1A2 135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.